Your browser version may not work well with NCBI's Web applications. More information here...
1: Nat Genet. 2006 Sep;38(9):1071-6. Epub 2006 Aug 6.
Related Articles, Links
Click here to read Click here to read
Comment in:
JAK signaling globally counteracts heterochromatic gene silencing.

Shi S, Calhoun HC, Xia F, Li J, Le L, Li WX.

Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, New York 14642, USA.

The JAK/STAT pathway has pleiotropic roles in animal development, and its aberrant activation is implicated in multiple human cancers. JAK/STAT signaling effects have been attributed largely to direct transcriptional regulation by STAT of specific target genes that promote tumor cell proliferation or survival. We show here in a Drosophila melanogaster hematopoietic tumor model, however, that JAK overactivation globally disrupts heterochromatic gene silencing, an epigenetic tumor suppressive mechanism. This disruption allows derepression of genes that are not direct targets of STAT, as evidenced by suppression of heterochromatin-mediated position effect variegation. Moreover, mutations in the genes encoding heterochromatin components heterochromatin protein 1 (HP1) and Su(var)3-9 enhance tumorigenesis induced by an oncogenic JAK kinase without affecting JAK/STAT signaling. Consistently, JAK loss of function enhances heterochromatic gene silencing, whereas overexpressing HP1 suppresses oncogenic JAK-induced tumors. These results demonstrate that the JAK/STAT pathway regulates cellular epigenetic status and that globally disrupting heterochromatin-mediated tumor suppression is essential for tumorigenesis induced by JAK overactivation.

Publication Types:
PMID: 16892059 [PubMed - indexed for MEDLINE]